GBS Inc. (GBS)
Company Description
GBS Inc. operates as a biosensor diagnostic technology company in the Asia-Pacific and North America.
It offers Saliva Glucose Biosensor, an organic thin-film transistor for diabetes management that measures glucose in saliva.
The company also focuses on developing SARS-CoV-2 Biosensor, a biosensor test can be used as a complement to the (RNA) virus detection test; and a biosensor platform comprising of biochemistry, immunology, tumor markers, hormones, and nucleic acid diagnostic modalities.
GBS Inc. has a research agreement with Johns Hopkins Bloomberg School of Public Health for the development of saliva-based diagnostic tests.
The company was formerly known as Glucose Biosensor Systems (Greater China) Holdings, Inc. and changed its name to GBS Inc. in September 2019.
The company was incorporated in 2016 and is headquartered in New York, New York.
GBS Inc. is a subsidiary of Life Science Biosensor Diagnostics Pty Ltd.

Country | United States |
IPO Date | Dec 23, 2020 |
Industry | Medical - Devices |
Sector | Healthcare |
Employees | 12 |
CEO | Harry Simeonidis |
Contact Details
Address: 708 3rd Avenue New York, New York United States | |
Website | https://gbs.inc |
Stock Details
Ticker Symbol | GBS |
Exchange | NASDAQ |
Fiscal Year | July - June |
Reporting Currency | USD |
CIK Code | 0001725430 |
CUSIP Number | |
ISIN Number | US36151G1058 |
Employer ID | 82-1512711 |
SIC Code | 3841 |
Key Executives
Name | Position |
---|---|
Dr. Stephen Constantine Boyages M.D., MBBS, Ph.D. | Interim Chief Executive Officer & Chairman |
Spiro Kevin Sakiris B.Bus, C.A., CA, Dip Law | Chief Financial Officer |
Alex Arzeno | Vice President of Investor Relations |
Harry Simeonidis | Pres of Asia Pacific |
Victoria Gavrilenko | Operations Mang. |
Latest SEC Filings
Date | Type | Title |
---|---|---|
Apr 04, 2025 | SEC STAFF ACTION | Filing |
Apr 01, 2025 | ARS | Filing |
Apr 01, 2025 | DEF 14A | Filing |
Mar 31, 2025 | 4/A | [Amend] Filing |
Mar 26, 2025 | 8-K | Current Report |
Mar 25, 2025 | 8-K | Current Report |
Mar 21, 2025 | 8-K | Current Report |
Mar 14, 2025 | 8-K | Current Report |
Mar 12, 2025 | 8-K | Current Report |
Mar 11, 2025 | 424B5 | Filing |